Infinity’s IPI-145 Shoots From Phase I To Pivotal CLL Study
Executive Summary
Enrollment begins in Phase III study of IPI-145 in relapsed/refractory CLL, after releasing Phase I results at ASH that the company believes prove the drug is differentiated from other PI3 kinase inhibitors by potency.